Cytotoxic effect of some 1, 4-dihydropyridine derivatives containing nitroimidazole moiety

Iranian Journal of Pharmaceutical Research

Volumn 10, Issue 3, 2011, Pages 497-503

  Miri, Ramin ^a,b   Javidnia, Katayoun ^a,b   Amirghofran, Zahra ^a,c   Salimi, Seyyed Hossein ^a,b   Sabetghadam, Zahra ^a,b   Meili, Savis ^a,b   Mehdipour, Ahmad Reza ^a,b  

^a SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

1; 4 dihydropyridines; Cytotoxicity; MTT assay; Nitroimidazole

Indexed keywords

1, 4 DIHYDROPYRIDINE DERIVATIVE; DIHYDROPYRIDINE DERIVATIVE; NITROIMIDAZOLE; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CELL GROWTH; CONTROLLED STUDY; CYTOTOXICITY; DRUG INHIBITION; DRUG STRUCTURE; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IC 50; QUANTITATIVE STRUCTURE ACTIVITY RELATION;

EID: 84856963090     PISSN: 17350328     EISSN: 17266890     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Coburn RA, Wierzba M, Suto MJ, Solo AJ, Triggle AM and Triggle DJ. 1, 4-Dihydropyridine antagonist activities at the calcium channel: a quantitative structure-activity relationship approach. J. Med. Chem. (1988) 31: 2103-2107.
2. Shekarchi M, Binesh Marvasti M, Sharifzadeh M and Shafiee A. Anticonvulsant activities of 7-phenyl-5H-thiazolo[5, 4-e][1, 2, 3, 4]tetrazolo[5, 1-c]pyrrolo[1, 2-a][1, 4]diazepine and 7-phenyl-5H-thiazolo[5, 4-e][1, 3, 4]triazolo[5, 1-c] pyrrolo[1, 2-a][1, 4]diazepines. Iranian J. Pharm. Res. (2005) 4: 33-36.
3. Miri R, Javidnia K, Sarkarzadeh H and Hemmateenejad B. Synthesis, study of 3D structures, and pharmacological activities of lipophilic nitroimidazolyl-1, 4-dihydropyridines as calcium channel antagonist. Bioorg. Med. Chem. (2006) 14: 4842-4849.
4. Velazquez C and Knaus EE. Synthesis and biological evaluation of 1, 4-dihydropyridine calcium channel modulators having a diazen-1-ium-1, 2-diolate nitric oxide donor moiety for the potential treatment of congestive heart failure. Bioorg. Med. Chem. (2004) 12: 3831-3840.
5. Bodor N. Redox drug delivery systems for targeting drugs to the brain. Ann. NY. Acad. Sci. (1987) 507: 289-306.
6. Mortazavi SM. Advances in targeted drug delivery. Iranian J. Pharm. Res. (2007) 6 149-150.
7. Kaymaz AA, Tan H, Altug T and Buyukdevrim AS. The effects of calcium channel blockers, verapamil, nifedipine and diltiazem, on metabolic control in diabetic rats. Diabetes Res. Clin. Pract. (1995) 28: 201-205.
8. Miri R, Javidnia K, Kebriaie-Zadeh A, Niknahad H, Shaygani N, Semnanian S and Shafiee A. Synthesis and evaluation of pharmacological activities of 3, 5-dialkyl 1, 4-dihydro-2, 6-dimethyl-4-nitroimidazole-3, 5-pyridine dicarboxylates. Arch. Pharm. (Weinheim) (2003) 336: 422-428.
9. Kawase M and Motohashi N. New multidrug resistance reversal agents. Curr. Drug Targets (2003) 4: 31-43.
10. Mehdipour AR, Javidnia K, Hemmateenejad B, Amirghofran Z and Miri R. Dihydropyridine derivatives to overcome atypical multidrug resistance: design, synthesis, QSAR studies, and evaluation of their cytotoxic and pharmacological activities. Chem. Biol. Drug Des. (2007) 70: 337-346.
11. Zhou XF, Yang X, Wang Q, Coburn RA and Morris ME. Effects of dihydropyridines and pyridines on multidrug resistance mediated by breast cancer resistance protein: in-vitro and in-vivo studies. Drug Metab. Dispos. (2005) 33: 1220-1228.
12. Gietzen K, Abdallah F and Bai G. Inhibition of tumor cell growth by a novel dihydropyridine derivative. Eur. J. Cancer (1990) 26: 922-923.
13. Hahn KA, Legendre AM and Schuller HM. Amputation and dexniguldipine as treatment for canine appendicular osteosarcoma. J. Cancer Res. Clin. Oncol. (1997) 123: 34-38.
14. Jorjani M, Rastegar H, Roshanzamir F, Varmazyari M, Abdollahi M and Zarghi A. Synthesis and biological evaluation of new 1, 4-dihydropyridines as antihypertensives agents in rats. Iranian J. Pharm. Res. (2003) 2: 43-46.
15. Morshed SR, Hashimoto K, Murotani Y, Kawase M, Shah A, Satoh K, Kikuchi H, Nishikawa H, Maki J and Sakagami H. Tumor-specific cytotoxicity of 3,5-dibenzoyl-1,4-dihydropyridines. Anticancer Res. (2005) 25: 2033-2038.
16. Fedeli L, Colozza M, Boschetti E, Sabalich I, Aristei C, Guerciolini R, Del Favero A, Rossetti R, Tonato M, Rambotti P and Davis S. Pharmacokinetics of vincristine in cancer patients treated with nifedipine. Cancer (1989) 64: 1805-1811.
17. 2+ channels. Kidney Int. (1996) 49: 868-879.
18. Straub T, Boesenberg C, Gekeler V and Boege F. The dihydropyridine dexniguldipine hydrochloride inhibits cleavage and relegation reactions of eukaryotic DNA topoisomerase I. Biochemistry (1997) 36: 10777-10783.
19. Miri R, Dehpour AR, Azimi M and Shafiee A. Synthesis and smooth muscle calcium channel antagonist effect of alkyl, aminoalkyl 1, 4-dihydro-2, 6-dimethyl-4-nitroimidazole-3,5 pyridine dicarboxylates. Daru (2001) 9: 40-45.
20. Miri R, Javidnia K, Mirkhani H, Hemmateenejad H, Kazemi Z, Edraki N and Mehdipour AR. Synthesis and in-vitro dual calcium channel antagonist-agonist activity of some 1, 4-dihydo-2, 6-dimethyl-3-nitro and cyano-4-(1-methyl-5-nitro-1H-imidazol-2-yl)-5-pyridinecarboxylates. Daru (2008) 16: 263-270.
21. Miri R, Niknahad H, Vazin A, Azarpira A and Shafiee A. Synthesis and smooth muscle calcium channel antagonist effects of new derivatives of 1,4-dihydropyridine containing nitroimidazolyl substituent. Daru (2002) 10: 130-136.
22. Miri R, Niknahad H, Vesal G and Shafiee A. Synthesis and calcium channel antagonist activities of 3-nitrooxyalkyl, 5-alkyl 1,4-dihydro-2,6-dimethyl-4-(1-methyl-5-nitro-2-imidazolyl)-3, 5-pyridinedicarboxylates. Farmaco. (2002) 57: 123-128.
23. Shafiee A, Miri R, Dehpour AR and Soleymani F. Synthesis and calcium-channel antagonist activity of nifedipine analogues containing nitroimidazolyl substituent in guinea-pig ileal smooth muscle. Pharm. Sci. (1996) 2: 541-543.
24. Jabbar SA, Twentyman PR and Watson JV. The MTT assay underestimates the growth inhibitory effects of interferons. Br. J. Cancer (1989) 60: 523-528.
25. Mehdipour AR, Hemmateenejad B and Miri R. QSAR studies on the anesthetic action of some polyhalogenated ethers. Chem. Biol. Drug Des. (2007) 69: 362-368.
26. Hughes JD, Blagg J, Price DA, Bailey S, Decresceno GA, Devraj RV, Ellsworth E, Fobian YM, Gibbs ME, Gills RW, Greene N, Huang E, Krieger-Burke T, Loesel J, Wager T, Whiteley L and Zhang Y. Physiochemical drug properties associated with in-vivo toxicological outcomes. Bioorg. Med. Chem. Lett. (2008) 18: 4872-4875.
27. Brezden CB, Horn L, McClelland RA and Rauth AM. Oxidative stress and 1-methyl-2-nitroimidazole cytotoxicity. Biochem. Pharmacol. (1998) 56: 335-344.
28. Lee HH, Palmer BD, Wilson WR and Denny WA. Synthesis and hypoxia-selective cytotoxicity of 2-nitroimidazole mustard. Bioorg. Med. Chem. Lett. (1998) 8: 1741-1744.
29. Moselen JW, Hay MP, Denny WA and Wilson WR. N-[2-(2-methyl-5-nitroimidazolyl) ethyl]-4-(2-nitroimidazolyl)butanamide (NSC 639862), a bisnitroimidazole with enhanced selectivity as a bioreductive drug. Cancer Res. (1995) 55: 574-580.
30. Ford JM and Hait WN. Pharmacology of drugs that alter multidrug resistance in cancer. Pharmacol. Rev. (1990) 42: 155-199.
31. Tasaka S, Ohmori H, Gomi N, Lino M, Machida T, Kiue A, Natio S and Kuwano M. Synthesis and structure-activity analysis of novel dihydropyridine derivatives to overcome multidrug resistance. Bioorg. Med. Chem. Lett. (2001) 11: 275-257.
32. Mohajeri A, Hemmateenejad B, Mehdipour A and Miri R. Modeling calcium channel antagonistic activity of dihydropyridine derivatives using QTMS indices analyzed by GA-PLS and PC-GA-PLS. J. Mol. Graph. Model. (2008) 26: 1057-1065.